UCLA study: Insomnia therapy slows biological aging in older adults

Researchers at UCLA Health have found that treating insomnia with cognitive behavioral therapy not only helps older adults sleep better—it appears to slow the biological aging process itself. The discovery, published in The Lancet Healthy Longevity, suggests that what has long been dismissed as merely a quality-of-life problem may actually be a lever for extending healthspan in aging populations.

The study enrolled nearly 100 older adults with clinical insomnia and randomly assigned them to one of two interventions. Half received cognitive behavioral therapy for insomnia, a structured clinical approach that targets the thoughts and behaviors that perpetuate sleeplessness over multiple sessions with a trained therapist. The other half received sleep education therapy—essentially informational content about sleep hygiene and healthy sleep habits, without the behavioral intervention. Before treatment began and again over the following two years, researchers drew blood and extracted DNA to measure biological aging using three different epigenetic clocks: DunedinPACE, GrimAge, and PC-PhenoAge. These tools measure aging at the molecular level by tracking changes in DNA methylation, the chemical process that turns genes on and off.

The results were striking. Adults who underwent cognitive behavioral therapy were nearly three times more likely to achieve remission from insomnia compared to those who received sleep education alone. More significantly, the therapy group showed a measurably slower pace of biological aging according to the DunedinPACE epigenetic clock—a finding that suggests the intervention was not simply improving sleep but actually altering how quickly the body ages at a cellular level.

The stakes of this discovery are substantial. Between 10 and 25 percent of Americans over 65 experience clinical insomnia. Previous research has established a link between chronic insomnia and accelerated biological aging, which in turn increases the risk of age-related diseases including cardiovascular disease, diabetes, and premature mortality. Insomnia has typically been treated as a comfort issue, something that affects quality of life but not necessarily lifespan. This study reframes it as a modifiable risk factor—something physicians can actively address to slow aging itself.

Dr. Judith Carroll, the study's lead author and an associate professor of psychiatry at UCLA Health, emphasized the clinical implications. She noted that physicians already counsel patients on physical activity and diet as cornerstones of healthy aging. The new findings suggest sleep deserves equal standing in that conversation. The distinction between the two treatments is instructive: simply knowing about good sleep habits is not enough. The structured, behavioral work of cognitive behavioral therapy—the active process of identifying and changing the thoughts and behaviors that keep someone awake—appears to be what drives both remission and the measurable slowing of biological aging.

What remains to be determined is whether the aging benefits persist long-term, how they compare across different populations, and whether other insomnia treatments might produce similar effects. But for now, the research points toward a straightforward clinical opportunity: treating insomnia in older adults not as a minor complaint but as a modifiable factor in how the body ages.